Evicel Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Evicel market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historical period can be attributed to an increase in the number of surgical procedures, a rise in the prevalence of chronic diseases, growing demand for effective hemostatic agents, expanding healthcare infrastructure, increased demand for minimally invasive surgeries, higher prevalence of chronic conditions requiring surgical intervention, and a rise in healthcare investments.

Growth during the market's forecast period can be attributed to the rising demand for minimally invasive surgeries, increasing prevalence of chronic diseases requiring complex surgical procedures, expanding healthcare infrastructure in emerging markets, a growing focus on faster recovery times in surgeries, increased awareness of hemostatic products, and the integration of surgical sealants into a broader range of medical fields. Key trends expected during the forecast period include the development of next-generation fibrin sealants, incorporation of advanced delivery systems, advancements in regulatory approvals for quicker product availability, adoption of biomimetic and bio-based materials, innovations in fibrin sealant formulations, and integration with automated surgical systems.

The increasing prevalence of bleeding disorders is anticipated to drive the growth of the evicel market. Bleeding disorders are medical conditions in which blood does not clot properly, leading to excessive or prolonged bleeding after injury or surgery. The rise in bleeding disorders can be attributed to factors such as the growing incidence of genetic conditions such as hemophilia, lifestyle issues such as poor nutrition and obesity, and an increase in chronic illnesses such as liver disorders, which impair the body's ability to clot. Evicel, a fibrin sealant, is used to promote hemostasis during surgical procedures, particularly in patients with coagulation challenges, including those with hemophilia or other clotting deficiencies. For example, in September 2022, the Perth Blood Institute, an Australia-based non-profit organization, reported that cases of hemophilia A rose from 185,318 in 2021 to 208,957 in 2022, while cases of hemophilia B increased from 37,998 to 43,203, representing growth rates of 12.8% and 13.7%, respectively. Consequently, the increasing prevalence of bleeding disorders is driving the growth of the evicel market.

The growing prevalence of chronic conditions is also expected to boost the growth of the evicel market. Chronic conditions are long-term illnesses lasting a year or more that require ongoing care or limit daily activities, such as diabetes and heart disease. These conditions are rising due to aging populations, unhealthy lifestyles, environmental influences, and improved diagnostic capabilities, highlighting both lifestyle and systemic factors. Evicel is frequently used as a fibrin sealant to manage bleeding during surgeries, especially in patients with chronic diseases that can hinder wound healing or clotting. Its use supports achieving hemostasis and reduces complications during surgical interventions in these patients. For instance, in March 2024, the Office for Health Improvement & Disparities, a UK-based government department, reported that between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes, it rose by 21%. Additionally, the percentage of patients achieving target HbA1c levels climbed to 37.9%, the highest recorded value. Therefore, the increasing prevalence of chronic conditions is driving the growth of the evicel market.

The rising demand for aesthetic surgeries is expected to further propel the growth of the evicel market. Aesthetic surgeries include minimally invasive or non-invasive procedures aimed at improving physical appearance, enhancing skin texture, and addressing signs of aging such as wrinkles, fine lines, and sagging skin. The growing popularity of aesthetic procedures is driven by factors such as higher disposable incomes, aging populations, social media influence, and advancements in cosmetic technologies. Evicel is used in aesthetic surgeries to ensure precise wound closure and minimize post-operative complications. Its application supports reduced scarring and enhanced healing, meeting the high standards required in cosmetic procedures. For instance, in September 2023, the International Society of Aesthetic Plastic Surgery (ISAPS), a US-based organization dedicated to advancing aesthetic plastic surgery, reported that over 33.7 million aesthetic procedures were performed globally in 2022, reflecting an 11.2% increase from 2021. As a result, the growing demand for aesthetic surgeries is driving the expansion of the evicel market.

The key company operating in the evicel market is Johnson & Johnson (Omrix Biopharmaceuticals Ltd).

North America was the largest region in the evicel market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in evicel report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the evicel market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Evicel is a surgical fibrin sealant derived from human fibrinogen and thrombin, designed to stop bleeding and promote healing by forming a clot during surgical procedures. It is commonly used in surgeries that require precise bleeding control, such as cardiovascular, liver, and orthopedic operations. Its biocompatibility minimizes the risk of adverse reactions, ensuring patient safety.

The primary surgical applications of evicel include orthopedic surgeries, cardiac surgeries, general surgeries, liver surgeries, and gynecological surgeries. Orthopedic surgeries address musculoskeletal conditions such as fractures, joint replacements, and spinal issues. These procedures often require hemostatic agents such as Evicel to control bleeding, especially during complex operations such as hip replacements or spinal surgeries. Evicel is distributed through hospital pharmacies, surgical supply distributors, and outpatient surgery centers, and it is utilized in hospitals, specialty clinics, and other healthcare settings.

The evicel market research report is one of a series of new reports that provides evicel market statistics, including evicel industry global market size, regional shares, competitors with a evicel market share, detailed evicel market segments, market trends and opportunities, and any further data you may need to thrive in the evicel industry. This evicel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The evicel market consists of sales of fibrin sealant kits, hemostatic applicators, wound closure aids, and spray applicators. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.